Hospital-Made cancer fighters: new CAR-T trial for leukemia

NCT ID NCT07371403

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, which are collected, modified to target cancer cells, and then infused back. The main goal is to see if the cells can be made successfully on-site, with a secondary look at how well they work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MB-CART19.1 (a type of CAR-T cell therapy made from the patient's own immune cells)

What this could lead to

If successful, this could show that making CAR-T cells at the hospital is possible, potentially offering a faster and more accessible treatment for patients with relapsed or refractory B-ALL.

What could go wrong

This is a very small, early feasibility study with only 12 participants. It focuses on whether the cells can be made, not yet on how well they work. The therapy may not be effective or could cause serious side effects like cytokine release syndrome.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma refractory precursor T-lymphoblastic lymphoma/leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • King Hussein Cancer Center

    RECRUITING

    Amman, 11941, Jordan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••